These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.Dividend-paying stocks have been dominant performers in the U.S. market since 1900. Their power lies in compounding, which can substantially increase returns over time.Companies that consistently raise their dividends frequently outperform the S&P 500 over long periods. These dividend growers often feature strong fundamentals, proven business models, and management teams focused on shareholder ret ...

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.The CBO estimates this Medicare coverage could increase federal spending by $35 billion from 2026 to 2034, underscoring the significant sales potential for GLP-1 drugs in the weight loss market. Investors have resp ...

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.Most investors are aware of the vast sales potential for the effective new weight loss treatments known as GLP-1 drugs, and the market for them is still relatively quite young. On Tuesday, the Congressional Budget Office (CBO) put a number on one piece of that market's potential. As that figure was large, weight loss drug producer Eli Lilly (LLY 1.70%) saw a nearly 2% bump in its share price in response. That compa ...

 SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule therapeutics to the brain, announced today that it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for brain transport. Under this collaboration agreement, Qinotto will partner with Lilly Catalyze360-ExploR&D (https:// ...

The Outsourcing Facilities Association, representing companies producing generic versions of Eli Lilly's (LLY, Financial) weight loss drug, has filed a lawsuit against the U.S. Food and Drug Administration (FDA) in a Texas federal court. The group claims that the FDA's decision to remove Eli Lilly's drug from the shortage list was "arbitrary, capricious, and unlawful." This decision, they argue, limits patient access to crucial medications, prompting a request for the court to overturn or modify the FDA's r ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.Eli Lilly (LLY 1.27%) stock has climbed in the double digits over the past year thanks to its leading position in one of the highest-growth pharmaceutical markets around: weight loss drugs. Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight control. Doctors have prescribed both for the weight loss indication though, and demand has been so high that it' ...

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance.  Large drugmakers have several robust revenue streams and are mostly profitable companies, which makes them safe havens for investments. Innovation is key to the growth of the industry. Innovation ...

In the latest market close, Eli Lilly (LLY) reached $887.16, with a +0.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.Shares of the drugmaker have depreciated by 2.98% over the course of the past month, outperforming the Medical sector's loss of 4.05% and lagging the S&P 500's gain of 3.15%.The upcoming earnings release of Eli Lilly will be of great interest to investors. It is anticipated ...

Thursday, The FDA determined the shortage of Eli Lilly And Co’s LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs.The FDA noted that Novo Nordisk A/S‘ NVO semaglutide (Wegovy, Ozempic) is still in shortage.Despite semaglutide being the active ing ...

Eli Lilly and Company (LLY) announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable the development of new methods for making its drugs and also scale up the supply of medicines for clinical trials for Lilly's growing pipeline. This one-of-a-kind facility, which combines research and manufacturing in a single location, will open in 2027. The Medicine Foundry, which is expected to creat ...